Management of Soil-transmitted Helminthiasis and Strongyloidiasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01308268|
Recruitment Status : Unknown
Verified February 2011 by Universidad Nacional de Salta.
Recruitment status was: Recruiting
First Posted : March 4, 2011
Last Update Posted : March 4, 2011
|Condition or disease||Intervention/treatment||Phase|
|Helminthiasis Strongyloides Stercoralis Infection||Drug: Ivermectin + Albendazole||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||April 2012|
|Estimated Study Completion Date :||April 2012|
- Drug: Ivermectin + Albendazole
Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (>= 2 years old) single dose, PO
- Evaluation of local epidemiology of soil-transmitted helminthiases and impact of a mass drug treatment anti-helminthic strategy [ Time Frame: 15 months ]
Evaluate local epidemiology of STH: frequency of species, prevalence and intensity of infections, groups more affected, morbidity.
Evaluate the efficacy of a single-dose anti-helminthic regimen for community treatments: albendazole 400 mg + ivermectin 200 mcg/kg.
- Validate serology methods for diagnosis of S. stercoralis infection [ Time Frame: 15 months ]Compare sensibility, specificity and predictive values of serology for S.stercoralis (ELISA-NIE) with traditional coproparasitological methods
- Assess the tolerability and safety of the combination of ivermectin and albendazole [ Time Frame: 15 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01308268
|Contact: Alejandro Krolewiecki, MD, PhDemail@example.com|
|Contact: María E Socías, MDfirstname.lastname@example.org|
|Instituto de Investigación en Enfermedades Tropicales, Universidad Nacional de Salta||Recruiting|
|Orán, Salta, Argentina, 4530|
|Principal Investigator:||Alejandro Krolewiecki, MD, PhD||Universidad Nacional de Salta, Instituto de Investigación en Enfermedades Tropicales|